Financing ·
Radiopharm Theranostics Limited announced a concurrent US$4.1 million registered direct offering of 1,281,646 ADSs at…
RADXRadiopharm Theranostics Ltd
Radiopharm Theranostics Limited announced a concurrent US$4.1 million registered direct offering of 1,281,646 ADSs at US$3.16 per ADS, alongside an Australian placement and share purchase plan to raise up to A$12.7 million (US$8.9 million). The company intends to use the proceeds to support the RAD101 registrational study, clinical milestones, and working capital. Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing oncology radiopharmaceuticals.